Return on capital (ROC) is after tax rate of return on net business assets. ROIC is unaffected by changes in interest rates or company debt and equity structure. It measures business productivity performance.
Return on Invested Capital (ROIC)
| Dec 31, 2020 | Dec 29, 2019 | Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net operating profit after taxes (NOPAT)1 | 593) | 957) | 775) | 739) | 453) | |
| Invested capital2 | 4,907) | 4,997) | 3,989) | 3,596) | 2,874) | |
| Performance Ratio | ||||||
| ROIC3 | 12.08% | 19.15% | 19.42% | 20.55% | 15.77% | |
| Benchmarks | ||||||
| ROIC, Competitors4 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
1 NOPAT. See details »
2 Invested capital. See details »
3 2020 Calculation
ROIC = 100 × NOPAT ÷ Invested capital
= 100 × 593 ÷ 4,907 = 12.08%
4 Click competitor name to see calculations.
An analysis of the financial performance from 2016 to 2020 reveals a trajectory of initial expansion in capital efficiency followed by a notable contraction. While profitability and the capital base grew concurrently for several years, the relationship between these two metrics shifted significantly in the final year of the period.
- Net Operating Profit After Taxes (NOPAT)
- NOPAT exhibited a strong upward trend from 2016 to 2019, increasing from 453 million USD to a peak of 957 million USD. This growth phase was interrupted in 2020, when NOPAT declined to 593 million USD, marking a significant reduction in operating profitability.
- Invested Capital
- The invested capital base expanded consistently from 2016 through 2019, rising from 2,874 million USD to 4,997 million USD. In 2020, this expansion ceased, with the capital base remaining relatively stable at 4,907 million USD.
- Return on Invested Capital (ROIC)
- ROIC experienced a sharp increase between 2016 and 2017, rising from 15.77% to a peak of 20.55%. A period of gradual decline followed, with the ratio drifting down to 19.15% by 2019. A substantial contraction occurred in 2020, with ROIC falling to 12.08%. This decline is primarily attributable to the decrease in NOPAT occurring while the invested capital base remained elevated.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Decomposition of ROIC
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
1 Operating profit margin (OPM). See calculations »
2 Turnover of capital (TO). See calculations »
3 Effective cash tax rate (CTR). See calculations »
The Return on Invested Capital (ROIC) exhibited a period of growth followed by a significant contraction over the five-year analysis period. After reaching a peak of 20.55% in 2017, the ROIC trended downward, concluding at a period low of 12.08% in 2020.
- Operating Profit Margin (OPM)
- Operational profitability demonstrated significant volatility. A sharp increase to 39.36% in 2017 was the primary driver behind the peak in ROIC. Subsequently, the margin experienced an overall decline, falling to 19.37% by 2020, which suggests increasing operational costs or pricing pressures that negatively impacted the bottom line.
- Turnover of Capital (TO)
- The efficiency of capital utilization showed a deteriorating trend. Following a peak of 0.84 in 2018, the turnover ratio declined consistently to 0.66 by 2020. This reduction indicates a decrease in the company's ability to generate revenue from its invested capital base.
- Tax Efficiency (1 – Effective Cash Tax Rate)
- A consistent upward trend is observed in the after-tax component. From a low of 68.24% in 2017, the ratio climbed steadily to 94.45% in 2020. This improvement suggests a lower effective cash tax burden over time, which served as a partial buffer against the decline in operating performance.
The decomposition of ROIC indicates that the decline in overall returns was driven by the simultaneous erosion of operating margins and capital turnover. Although the increase in tax efficiency provided a positive contribution to the return, it was not sufficient to counteract the weakening operational efficiency and diminishing profitability observed between 2018 and 2020.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Operating Profit Margin (OPM)
| Dec 31, 2020 | Dec 29, 2019 | Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net operating profit after taxes (NOPAT)1 | 593) | 957) | 775) | 739) | 453) | |
| Add: Cash operating taxes2 | 35) | 114) | 133) | 344) | 140) | |
| Net operating profit before taxes (NOPBT) | 627) | 1,071) | 907) | 1,083) | 594) | |
| Revenue | 3,239) | 3,543) | 3,333) | 2,752) | 2,398) | |
| Profitability Ratio | ||||||
| OPM3 | 19.37% | 30.23% | 27.22% | 39.36% | 24.75% | |
| Benchmarks | ||||||
| OPM, Competitors4 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2020 Calculation
OPM = 100 × NOPBT ÷ Revenue
= 100 × 627 ÷ 3,239 = 19.37%
4 Click competitor name to see calculations.
Between 2016 and 2020, the company experienced a period of revenue expansion followed by a contraction, accompanied by significant volatility in operating profitability. While revenue trended upward through 2019, the operating profit margin exhibited an inconsistent trajectory, suggesting that operating expenses did not scale linearly with sales.
- Revenue Trajectory
- Revenue increased steadily from US$ 2,398 million in 2016 to a peak of US$ 3,543 million in 2019. However, this growth trend reversed in 2020, with revenue declining to US$ 3,239 million.
- Net Operating Profit Before Taxes (NOPBT)
- NOPBT showed substantial variance, rising sharply from US$ 594 million in 2016 to US$ 1,083 million in 2017. After a decrease in 2018 and a recovery to US$ 1,071 million in 2019, the figure dropped significantly to US$ 627 million by the end of 2020, aligning with the decline in total revenue.
- Operating Profit Margin (OPM) Analysis
- The operating profit margin peaked at 39.36% in 2017, representing the highest level of operational efficiency in the five-year period. This was followed by a decline to 27.22% in 2018 and a modest recovery to 30.23% in 2019. The period concluded with a sharp contraction in 2020, where the margin fell to 19.37%, marking the lowest operational efficiency point in the observed timeframe.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Turnover of Capital (TO)
| Dec 31, 2020 | Dec 29, 2019 | Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Revenue | 3,239) | 3,543) | 3,333) | 2,752) | 2,398) | |
| Invested capital1 | 4,907) | 4,997) | 3,989) | 3,596) | 2,874) | |
| Efficiency Ratio | ||||||
| TO2 | 0.66 | 0.71 | 0.84 | 0.77 | 0.83 | |
| Benchmarks | ||||||
| TO, Competitors3 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
1 Invested capital. See details »
2 2020 Calculation
TO = Revenue ÷ Invested capital
= 3,239 ÷ 4,907 = 0.66
3 Click competitor name to see calculations.
The analysis of capital efficiency from 2016 to 2020 reveals a general decline in the turnover of capital, indicating a diminishing capacity to generate revenue relative to the amount of capital invested in the business.
- Revenue Trends
- Revenue exhibited consistent growth between 2016 and 2019, rising from US$ 2,398 million to a peak of US$ 3,543 million. However, this growth trend reversed in 2020, with revenue declining to US$ 3,239 million.
- Invested Capital Expansion
- Invested capital grew steadily and significantly over most of the period, increasing from US$ 2,874 million in 2016 to US$ 4,997 million in 2019. A slight contraction occurred in 2020, with capital settling at US$ 4,907 million.
- Turnover of Capital Efficiency
- The turnover of capital ratio remained relatively stable between 2016 and 2018, fluctuating between 0.77 and 0.84. A notable deterioration began in 2019, as the ratio dropped to 0.71, and further declined to 0.66 by the end of 2020. This downward trajectory suggests that the expansion of the capital base has outpaced revenue generation, resulting in reduced operational efficiency regarding capital utilization.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Effective Cash Tax Rate (CTR)
| Dec 31, 2020 | Dec 29, 2019 | Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net operating profit after taxes (NOPAT)1 | 593) | 957) | 775) | 739) | 453) | |
| Add: Cash operating taxes2 | 35) | 114) | 133) | 344) | 140) | |
| Net operating profit before taxes (NOPBT) | 627) | 1,071) | 907) | 1,083) | 594) | |
| Tax Rate | ||||||
| CTR3 | 5.55% | 10.66% | 14.61% | 31.76% | 23.65% | |
| Benchmarks | ||||||
| CTR, Competitors4 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Danaher Corp. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
| Vertex Pharmaceuticals Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2020 Calculation
CTR = 100 × Cash operating taxes ÷ NOPBT
= 100 × 35 ÷ 627 = 5.55%
4 Click competitor name to see calculations.
The analysis of the effective cash tax rate (CTR) from 2016 to 2020 reveals a significant and consistent downward trend following a peak in 2017.
- Effective Cash Tax Rate (CTR) Dynamics
- The CTR experienced an initial increase from 23.65% in 2016 to a period high of 31.76% in 2017. Following this peak, the rate declined precipitously over the subsequent three years, falling to 14.61% in 2018, 10.66% in 2019, and reaching a minimum of 5.55% by December 31, 2020. This trajectory indicates a substantial reduction in the cash tax burden relative to operating profits.
- Cash Operating Taxes and Profitability Correlation
- Cash operating taxes peaked at 344 million USD in 2017, which coincided with the highest recorded net operating profit before taxes (NOPBT) of 1,083 million USD. Despite NOPBT remaining relatively strong in 2018 and 2019—recording 907 million USD and 1,071 million USD respectively—cash operating taxes decreased sharply to 133 million USD and 114 million USD. By 2020, cash operating taxes reached a five-year low of 35 million USD, while NOPBT contracted to 627 million USD.
- Analysis of Tax Efficiency
- A decoupling is observed between operating profitability and cash tax outflows starting after 2017. While NOPBT fluctuated without a linear trend, the CTR and absolute cash taxes decreased monotonically from 2017 through 2020. This pattern suggests an increase in tax efficiency or the impact of deferred tax assets and tax credits, as the company maintained significant operating profits while paying progressively lower amounts of cash taxes.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?